Just caught Sana Biotech's latest earnings and there's actually some solid progress buried in the numbers. Stock's down 3% following the Q4 report, but if you look closer, the adjusted net loss actually tightened compared to last year—that's the kind of operational improvement biotech investors usually care about more than headline losses.

What caught my attention is their pipeline momentum. They're planning to file an IND for SC451, their stem-cell pancreatic islet therapy, as early as next year. For type 1 diabetes, they're essentially trying to create a one-time transplant that works without immunosuppression. The regulatory interactions with the FDA seem to be going well—they've completed INTERACT and Pre-IND meetings, which typically means the path forward is clearer.

The more interesting story though is UP421, their human pancreatic islet cell therapy that's currently in an investigator-sponsored trial. Here's what matters: a paper just published in NEJM showed their HIP-modified cells actually survived in a patient for a full year. The key metric everyone's watching is C peptide levels—that's basically the biomarker proving the transplanted beta cells are still producing insulin. The patient's C peptide actually increased during meal tolerance tests, meaning the transplanted cells were responding to food intake like normal pancreatic cells should. No immunosuppression needed. That's genuinely remarkable if it holds up.

They're also working on SG293, an in vivo CAR T program for blood cancers, with first human data expected this year and an IND filing targeted for 2027.

Cash position is $138.4 million with runway into late 2026, so they've got time to hit these milestones. Stock has ranged from $1.26 to $6.55 over the past year. The execution risk is real—moving from one successful transplant case to broader trials is a massive step—but if they can replicate what they saw with C peptide production and immune evasion in more patients, the market's probably underpricing this right now.